English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/151585
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis

AuthorsCabrera, Sonia; Gómara Elena, María José; Haro, Isabel ; Sanmartí, Raimon
KeywordsPalindromic rheumatism
Rheumatoid arthritis
Anticitrullinated peptide/protein antibodies
Vimentin
Issue Date15-Jun-2017
PublisherBioMed Central
CitationArthritis Research & Therapy 19(1): 141 (2017)
Abstract[Background] To analyze differences in the recognition of anti-citrullinated peptide/protein antibody (ACPA) citrullinated epitopes and isotypes in patients with palindromic rheumatism (PR) and rheumatoid arthritis (RA).
[Methods] ACPA fine specificities (citrullinated peptides of enolase, fibrin, and vimentin) and isotypes (IgG, IgM, and IgA) were analyzed in 54 patients with longstanding PR and 54 patients with established RA.
[Results] CCP2 tested positive in 66.7% of patients with PR and RA. The ACPA distribution of fine specificities and isotypes differed between PR and RA patients. PR patients had a lower frequency of fine ACPA specificities than RA patients, which was significant in the case of a peptide derived from vimentin (PR 24.1% vs. 59.3% RA; p < 0.001). The mean number of ACPA specificities was lower in PR than in RA patients, and only 25.9% of PR patients recognized ≥2 additional specificities compared with 46.3% of RA patients. Significantly less isotype usage, especially IgA, was observed in PR patients.
[Conclusion] The ACPA immune response differed in patients with PR and RA, with fewer fine specificities and isotype usage in patients with PR. Some patients with PR may have impaired maturation of the B-cell response against citrullinated peptides with no progression to RA.
Publisher version (URL)http://dx.doi.org/10.1186/s13075-017-1329-6
URIhttp://hdl.handle.net/10261/151585
DOI10.1186/s13075-017-1329-6
ISSN1478-6354
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
13075_2017_Article_1329.pdf683,42 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.